Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors
Clinical trial NCT00002193 · COMPLETED
Trial details
- NCT number
- NCT00002193
- Sponsor
- Glaxo Wellcome
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Enrollment
- 210
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.